Advertisement

Annals of Surgical Oncology

, Volume 14, Issue 8, pp 2289–2299 | Cite as

Critical Analysis of Treatment Failure After Complete Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Peritoneal Dissemination From Appendiceal Mucinous Neoplasms

  • Tristan D. Yan
  • Lana Bijelic
  • Paul H. Sugarbaker
Gastrointestinal Oncology

Abstract

Background

Cytoreductive surgery (CRS) combined with perioperative intraperitoneal chemotherapy (PIC) has been suggested as a treatment strategy for peritoneal carcinomatosis. The objective of this data analysis was to study treatment failure after complete cytoreduction for peritoneal dissemination from appendiceal mucinous neoplasms.

Methods

Before June 2006, a total of 402 patients with peritoneal dissemination from appendiceal mucinous neoplasms underwent complete cytoreduction and PIC at the Washington Cancer Institute. Patient characteristics, pathologic features, and treatment-related data were obtained from a prospective database. Survival analyses were performed by the Kaplan-Meier method and the Cox regression model.

Results

After a median follow-up of 66 months, the 5- and 10-year progression-free survival rates for these 402 patients were 70% and 67%, respectively. Disease progression was the only independent risk factor for a reduced overall survival. One hundred eleven patients (28%) developed progressive disease. Of these, 98 patients underwent second-time and 26 patients third-time CRS and PIC. Complete cytoreduction after repeat surgery was the only independent prognostic factor for improved survival. The most common sites of treatment failure were on the small bowel and in the pelvis.

Conclusions

The present study reported the patterns of treatment failure after complete cytoreduction and demonstrated that a disease-free state is important for long-term survival in peritoneal dissemination from appendiceal mucinous neoplasms. Repeat complete cytoreduction should be pursued when possible and is associated with improved overall survival in patients with recurrent disease.

Keywords

Pseudomyxoma peritonei Cytoreductive surgery Intraperitoneal chemotherapy Appendiceal neoplasms Recurrence Survival 

Notes

Acknowledgments

Tristan D. Yan and Lana Bijelic are surgical oncology research fellows supported by Foundation for Applied Research in Gastrointestinal Oncology. We thank David Chang for his assistance with the statistical analysis.

References

  1. 1.
    Miner TJ, Shia J, Jaques DP, et al. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg 2005;241:300–8PubMedCrossRefGoogle Scholar
  2. 2.
    Sugarbaker P. Are there curative options to peritoneal carcinomatosis? Ann Surg 2006;242:748–50CrossRefGoogle Scholar
  3. 3.
    Bryant J, Clegg AJ, Sidhu MK, et al. Systematic review of the Sugarbaker procedure for pseudomyxoma peritonei. Br J Surg 2005;92:153–8PubMedCrossRefGoogle Scholar
  4. 4.
    Smith JW, Kemeny N, Caldwell C, et al. Pseudomyxoma peritonei of appendiceal origin. The Memorial Sloan-Kettering Cancer Center experience. Cancer 1992;70:396–401PubMedCrossRefGoogle Scholar
  5. 5.
    Gough DB, Donohue JH, Schutt AJ, et al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg 1994;219:112–9PubMedCrossRefGoogle Scholar
  6. 6.
    Misdraji J, Yantiss R, Graeme-Cook F, et al. Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases. Am J Surg Pathol 2003;27:1089–103PubMedCrossRefGoogle Scholar
  7. 7.
    Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 2006;7:69–76PubMedCrossRefGoogle Scholar
  8. 8.
    Yan TD, Black D, Savady R, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 2007;14:484–92PubMedCrossRefGoogle Scholar
  9. 9.
    Elias D, Laurent S, Antoun S, et al. Pseudomyxoma peritonei treated with complete resection and immediate intraperitoneal chemotherapy. Gastroenterol Clin Biol 2003;27:407–12PubMedGoogle Scholar
  10. 10.
    Smeenk RM, Verwaal VJ, Zoetmulder FA. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei—a report of 103 procedures. Eur J Surg Oncol 2006;32:186–90PubMedCrossRefGoogle Scholar
  11. 11.
    Bradley RF, Stewart JHt, Russell GB, et al. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol 2006;30:551–9PubMedCrossRefGoogle Scholar
  12. 12.
    Loungnarath R, Causeret S, Bossard N, et al. Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: a prospective study. Dis Colon Rectum 2005;48:1372–9PubMedCrossRefGoogle Scholar
  13. 13.
    Guner Z, Schmidt U, Dahlke MH, et al. Cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei. Int J Colorectal Dis 2005;20:155–60PubMedCrossRefGoogle Scholar
  14. 14.
    Kusamura S, Younan R, Baratti D, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer 2006;106:1144–53PubMedCrossRefGoogle Scholar
  15. 15.
    Yan TD, Links M, Xu ZY, et al. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms. Br J Surg 2006;93:1270–6PubMedCrossRefGoogle Scholar
  16. 16.
    Ronnett BM, Zahn CM, Kurman RJ, et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei.” Am J Surg Pathol 1995;19:1390–408PubMedCrossRefGoogle Scholar
  17. 17.
    Jacquet P, Sugarbaker P. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 1996;15:49–58Google Scholar
  18. 18.
    Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995;221:29–42PubMedCrossRefGoogle Scholar
  19. 19.
    Gonzalez-Moreno S. Peritoneal surface oncology: a progress report. Eur J Surg Oncol 2006;32:593–6PubMedCrossRefGoogle Scholar
  20. 20.
    Sugarbaker PH, Alderman R, Edwards G, et al. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol 2006;13:635–44PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2007

Authors and Affiliations

  • Tristan D. Yan
    • 1
  • Lana Bijelic
    • 1
  • Paul H. Sugarbaker
    • 1
  1. 1.Peritoneal Surface Malignancy ProgramWashington Cancer Institute, Washington Hospital CenterWashingtonUSA

Personalised recommendations